European Union - English - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otologicals - dogs - treatment of acute otitis externa and acute exacerbations of recurrent otitis externa, associated with bacteria susceptible to orbifloxacin and fungi susceptible to posaconazole, in particular malassezia pachydermatis.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6), mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8), posaconazole (unii: 6tk1g07bhz) (posaconazole - unii:6tk1g07bhz) - indications: posatex® otic suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (malassezia pachydermatis) and bacteria (coagulase positive staphylococci, pseudomonas aeruginosa , and enterococcus faecalis ). contraindications : posatex® otic suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate, or posaconazole. do not use in dogs with known tympanic perforation (see precautions ).

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - mometasone furoate monohydrate; posaconazole; orbifloxacin - mometasone furoate monohydrate 1 g/kg; posaconazole 1 g/kg; orbifloxacin 10 g/kg - antibiotic

Israel - English - Ministry of Health

intervet ( israel) ltd - mometasone furoate (as monohydrate); orbifloxacin; posaconazole - ear drops suspension - orbifloxacin 8.5 mg/ml; mometasone furoate (as monohydrate) 0.9 mg/ml; posaconazole 0.9 mg/ml - dogs: treatment of acute otitis externa and acute exacerbations of recurrent otitis externa, associated with bacteria susceptible to orbifloxacin and fungi susceptible to posaconazole, in particular malassezia pachydermatis

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) - orbifloxacin 22.7 mg - indications: orbax® (orbifloxacin) tablets are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to orbifloxacin. contraindications: orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. orbifloxacin is contraindicated in immature dogs during the rapid growth phase (between 2 and 8 months of age in small and medium-sized breeds, and up to 18 months of age in large and giant breeds). orbifloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) - orbifloxacin 30 mg in 1 ml - indications: orbax® oral suspension is indicated for the treatment of urinary tract infections (cystitis) in dogs caused by susceptible strains of staphylococcus pseudintermedius, proteus mirabilis, escherichia coli and enterococcus faecalis . orbax® oral suspension is also indicated for skin and soft tissue infections (wounds and abscesses) in dogs caused by susceptible strains of staphylococcus pseudintermedius, staphylococcus aureus , coagulase positive staphylococci, pasteurella multocida, proteus mirabilis, pseudomonas spp., klebsiella pneumoniae, escherichia coli, enterobacter spp., citrobacter spp., enterococcus faecalis , β-hemolytic streptococci (group g) and streptococcus equisimilis . contraindications: orbifloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. orbifloxacin is contraindicated in immature dogs during the rapid growth phase (between 2 and 8 months of age

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - orbifloxacin - oral tablet - orbifloxacin antibiotic active 25.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - acinetobacter spp. | enterobacter spp. | enterococcus faecalis | escherichia coli (e. coli) | klebsiella pneumoniae | pasteurella multocida | proteus mirabilis | pseudomonas spp. | staphylococcus intermedius | streptococcus - hemolytic group g | deep pyodermas | fowl cholera | including b-lactamase producin | including secondary invaders | seborrhoeic dermatitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - orbifloxacin - oral tablet - orbifloxacin antibiotic active 6.25 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - acinetobacter spp. | enterobacter spp. | enterococcus faecalis | escherichia coli (e. coli) | klebsiella pneumoniae | pasteurella multocida | proteus mirabilis | pseudomonas spp. | staphylococcus intermedius | streptococcus - hemolytic group g | deep pyodermas | fowl cholera | including b-lactamase producin | including secondary invaders | seborrhoeic dermatitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - orbifloxacin - oral tablet - orbifloxacin antibiotic active 75.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - acinetobacter spp. | enterobacter spp. | enterococcus faecalis | escherichia coli (e. coli) | klebsiella pneumoniae | pasteurella multocida | proteus mirabilis | pseudomonas spp. | staphylococcus intermedius | streptococcus - hemolytic group g | deep pyodermas | fowl cholera | including b-lactamase producin | including secondary invaders | seborrhoeic dermatitis

United States - English - NLM (National Library of Medicine)

katayama seiyakusyo co., ltd. - orbifloxacin (unii: 660932tpy6) (orbifloxacin - unii:660932tpy6) -